{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.88","upperLimit":"46.97","value":"24.43"},{"groupId":"OG002","lowerLimit":"3.55","upperLimit":"3.55","value":"3.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"Time period from date of CT or MRI that first confirmed complete or partial response to date of CT or MRI that first confirmed progression of disease (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)","dispersionType":"Full Range","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All patients who achieved a partial or complete response","reportingStatus":"POSTED","timeFrame":"From first date of complete or partial response to first date of disease progression or death","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}